Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause, Including COVID-19 TORONTO, Ontario -…
Vasomune Therapeutics Announces Clinical and Scientific Advisory Board Esteemed Leaders in Translation, Therapeutic Development and Critical Care Medicine TORONTO, Ontario – (Business Wire) – May 11, 2020 – Vasomune Therapeutics,…
Vasomune Therapeutics Appoints Meenu Chhabra to its Board of Directors Industry Leader Joins Vasomune’s Board of Directors as the Company Transitions to Clinical Development of AV-001 for the treatment of COVID-19/Pathogen-induced…
An article in USA Today describes certain risks associated with contraction of the COVID-19 coronavirus, specifically the major cause of lethality being Acute Respiratory Distress Syndrome (ARDS). The article can…
Coronavirus (COVID-19) kills by inducing Acute Respiratory Distress Syndrome (ARDS). According to a recent article in The Lancet, 12 out of 41 (29%) COVID-19 patients from Wuhan, China developed ARDS…
Vasomune Therapeutics is currently attending the 38TH ANNUAL JPM HEALTHCARE CONFERENCE, San Francisco, California
Tokyo, Japan and Toronto, Ontario, July 31, 2018 (GLOBE NEWSWIRE) -- Vasomune Therapeutics (“Vasomune”), a Toronto-based spin-out from Sunnybrook Research Institute and MaRS Innovation, and AnGes, Inc. (Tokyo, TYO:4563), a Japan-based biotechnology…
In 2018 Vasomune Therapeutics will be at the 36TH ANNUAL JPM HEALTHCARE CONFERENCE, San Francisco, California
A New Flu Drug Works Astoundingly Well—By Not Targeting the Flu at All. Continue reading at Motherboard Vice.
Lifetime: New approach to fighting influenza Advertise on CTVNews.ca
Vasomune Therapeutics is a private biotechnology company developing AV-001, a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by AV-001 plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.
.